Ant Group Launches AI-Powered Mobile App Zhixiaobao at 2024 INCLUSION·Conference on the Bund
5.9.2024 10:55:00 CEST | Business Wire | Press release
Other AI-powered products were also introduced to make AI more accessible for industries and consumers
At the 2024 INCLUSION · Conference on the Bund in Shanghai, Ant Group launched the Zhixiaobao mobile app, an AI life assistant that better connects users with all kinds of life services on the company’s digital life platform Alipay. The app is available for download from iOS and Android app stores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904932587/en/
Ant Group unveiled AI life assistant app – Zhixiaobao, at the 2024 INCLUSION · Conference on the Bund. (Graphic: Business Wire)
As an AI-native application powered by Ant Group’s BaiLing foundation model, Zhixiaobao is designed to make everyday tasks easier through user-friendly interactions. Through typing or voice chat in Zhixiaobao, users can order meals, hail taxis, book tickets, and discover local dining and entertainment options, accessing third-party services in Alipay more easily.
The app also provides a number of built-in AI agents, each with specific domain knowledge that makes them an expert in their own fields. For example, the “English Language Tutor” agent can help users make a learning plan and provide tips for learning the language. The “Fitness Pro” agent can help users design workout routines and come up with personalized training advice.
"The evolution of AI extends beyond mere technological progress, it’s about applying these advancements to practical, user-focused solutions. Alipay is committed to harnessing AI’s potential to improve the user experience, ensuring that AI assistants like Zhixiaobao become valuable tools in everyday life for all," said Cyril Han, President of Ant Group.
To use Zhixiaobao’s services, users can either download the dedicated mobile app, or simply pull down the home page of the Alipay app.
In addition to Zhixiaobao, Ant Group also introduced other AI-powered products and solutions at the INCLUSION Conference.
- An AI Agent Development Platform: A comprehensive, one-stop platform enabling merchants to create customized AI service agents which can be deployed in just one minute, without the need for coding. These agents can be effortlessly integrated into the Alipay mini-programs operated by merchants, the Alipay app, and the Zhixiaobao app.
- AI Healthcare Manager: An AI-powered platform that connects users to over 30 health services, including doctor recommendations, medical test result interpretation, in-hospital navigation, and personalized medical advice. The AI Healthcare Manager is supported by over 20 service providers, including Renji Hospital in Shanghai.
- Ant Bridge: An open platform that leverages advanced technologies including AI models and financial intelligence, to assist insurance companies in providing personalized responses to customer inquiries in real-time. The platform is designed to support insurers to enhance their service quality while boosting operational efficiency.
Ant Group unveiled its BaiLing foundation model in 2023. Over the past two years, Ant Group has accelerated the application of AI technologies in the Alipay app, serving hundreds of millions of users across various life service use cases, including travel, healthcare, and financial management.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904932587/en/
Contacts
Media Inquiries
Media Inquiries
Vick Li Wei
vick.lw@antgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom